WE ARE FOCUSED ON ADDRESSING
OVERLOOKED NEEDS IN RARE BLOOD DISORDERS

WE ARE FOCUSED ON ADDRESSING OVERLOOKED NEEDS IN RARE BLOOD DISORDERS

Research efforts for rare blood disorders have led to treatment advances over the past several decades. Despite this progress, many patients continue to experience significant challenges and inadequate treatment options. We are committed to expanding the focus of rare blood disorder research to address these needs, starting with von Willebrand disease (VWD).

Research efforts for rare blood disorders have led to treatment advances over the past several decades. Despite this progress, many patients continue to experience significant challenges and inadequate treatment options. We are committed to expanding the focus of rare blood disorder research to address these needs, starting with von Willebrand disease (VWD).

Treatments Focused
on Fulfilling Unmet Needs

Treatments Focused
on Fulfilling Unmet Needs

VGA039, our lead antibody, is a Protein S modulator that can restore proper blood clotting in VWD.

VGA039, our lead antibody, is a Protein S modulator that can restore proper blood clotting in VWD.

A team focused on what matters

A team focused
on what matters

Our team members are passionate about resolving the unmet needs of patients.

Our team members are passionate about resolving the unmet needs of patients.

COLLECTIVELY FOCUSED ON ONE MISSION

COLLECTIVELY FOCUSED
ON ONE MISSION

Vega Therapeutics is a part of a constellation of companies led by Star Therapeutics, which focuses on developing life-changing therapies for patients with rare diseases.

Vega Therapeutics is a part of a constellation of companies led by Star Therapeutics, which focuses on developing life-changing therapies for patients with rare diseases.